Dr. Memarzadeh on Recurrence Rates in Ovarian Cancer

Sanaz Memarzadeh, MD, PhD
Published: Tuesday, Oct 13, 2015



Sanaz Memarzadeh, MD, PhD, gynecologic oncology, obstetrics and gynecology, University of California, Los Angeles, discusses recurrence rates in ovarian cancer.

The challenge with epithelial ovarian cancer, Memarzadeh says, is that the majority of patients present with advanced disease due to lack of identified biomarkers and little to no symptoms.

Therefore, in patients with stage III to IV epithelial ovarian cancer, approximately 80% to 85% relapse, despite undergoing surgeries and/or chemotherapy.



Sanaz Memarzadeh, MD, PhD, gynecologic oncology, obstetrics and gynecology, University of California, Los Angeles, discusses recurrence rates in ovarian cancer.

The challenge with epithelial ovarian cancer, Memarzadeh says, is that the majority of patients present with advanced disease due to lack of identified biomarkers and little to no symptoms.

Therefore, in patients with stage III to IV epithelial ovarian cancer, approximately 80% to 85% relapse, despite undergoing surgeries and/or chemotherapy.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x